Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Dulaglutide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 17Trulicity

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Eli Lilly

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 5,086

    2019 Revenue in Millions : 4,128

    Growth (%) : 23

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Dainippon Sumitomo

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 318

    2019 Revenue in Millions : 276

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Eli Lilly

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 6,472

    2020 Revenue in Millions : 5,086

    Growth (%) : 27

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Dainippon Sumitomo

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 285

    2020 Revenue in Millions : 318

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Dainippon Sumitomo

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 251

    2021 Revenue in Millions : 285

    Growth (%) : -12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Eli Lilly

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 7,440

    2021 Revenue in Millions : 6,472

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Dainippon Sumitomo

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2023 Revenue in Millions : 0

    2022 Revenue in Millions : 251

    Growth (%) : -100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Eli Lilly

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2023 Revenue in Millions : 7,133

    2022 Revenue in Millions : 7,440

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Eli Lilly

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2024 Revenue in Millions : 5,254

    2023 Revenue in Millions : 7,133

    Growth (%) : -26

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Trulicity

    Dulaglutide

    arrow
    Pharmex
    Not Confirmed

    Brand Name : Trulicity

    U.S.A
    arrow
    Pharmex
    Not Confirmed

    Eli Lilly

    Dulaglutide

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2015 Revenue in Millions : 10

    2014 Revenue in Millions : 249

    Growth (%) : 2390%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF